Skip to main content
Northwestern University Feinberg School of Medicine
Dmello Lab

Publications

Learn more about the work that we do in the Dmello Lab through our recent publications.

  1. Budhiraja S, Faisal UH, Baisiwala S, Chojak R, Koutah L, Drewes NB, Cho S, Kazi HA, Chen R, Perrault EN  et al.  THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression.  Neoplasia  2026 Jan 06;72:101271. pii:101271
  2. Youngblood MW, Kumari A, Kang YT, Gould A, Habashy K, Gomez M, Lingamarla H, Morey T, Chen L, Congivaram H  et al.  Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.  Nat Commun  2025 Dec 16;16(1):11045. pii:11045
  3. Hou D, Wang S, Castro BA, Katz JL, Dapash M, Arrieta VA, Vazquez-Cervantes GI, Wan H, Billingham LK, Du R  et al.  Dual aVß8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Tumor Immunity.  Neuro Oncol  2025 Oct 14;27(9):2355-2369. doi:10.1093/neuonc/noaf106
  4. Ali H, Zhou N, Chen L, van Hijfte L, Tulaiha R, Karri V, Zhou Y, Habashy K, Arrieta VA, Kim KS  et al.  YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.  Neuro Oncol  2025 Sep 30;. pii:noaf227
  5. Habashy KJ, Synold TW, Feng Y, Gomez C, Amidei C, Ward R, VanderMolen S, Zarrieneh A, Kim KS, Gomez M  et al.  Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.  Clin Cancer Res  2025 Aug 14;31(16):3562-3570. doi:10.1158/1078-0432.CCR-25-0080
  6. Qian H, Ali H, Karri V, Low JT, Ashley DM, Heimberger AB, Godley LA, Sonabend AM, Dmello C  Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.  Oncotarget  2025 Jun 10;16:445-453. doi:10.18632/oncotarget.28740
  7. Fares J, Petrosyan E, Dmello C, Lukas RV, Stupp R, Lesniak MS  Rethinking metastatic brain cancer as a CNS disease.  Lancet Oncol  2025 Feb;26(2):e111-e121. doi:10.1016/S1470-2045(24)00430-3
  8. Du R, Zhang J, Lukas RV, Tripathi S, Ahrendsen JT, Curran MA, Dmello C, Zhang P, Stupp R, Rao G  et al.  Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?  Neuro Oncol  2025 Jan 12;27(1):33-49. doi:10.1093/neuonc/noae193
  9. Gould A, Luan Y, Hou Y, Korobova FV, Chen L, Arrieta VA, Amidei C, Ward R, Gomez C, Castro B  et al.  Endothelial response to blood-brain barrier disruption in the human brain.  JCI Insight  2024 Dec 26;10(4). pii:e187328
  10. Dmello C, Brenner A, Piccioni D, Wen PY, Drappatz J, Mrugala M, Lewis LD, Schiff D, Fadul CE, Chamberlain M  et al.  Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.  Neurooncol Adv  2024;6(1):vdae186. pii:vdae186
  11. Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R, Arrieta VA, Dmello C, Chen L  et al.  Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.  Neuro Oncol  2024 Nov 04;26(11):2044-2060. doi:10.1093/neuonc/noae135
  12. Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Habashy K, Duffy J, Zhao J, Gould A, Chen L  et al.  MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacy.  bioRxiv  2024 Sep 18;. pii:2024.09.11.612571
  13. Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, Chen L, Park CH, Kazi HA, Dmello C  et al.  ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.  Neuro Oncol  2024 Aug 05;26(8):1421-1437. doi:10.1093/neuonc/noae059
  14. Najem H, Lea ST, Tripathi S, Hurley L, Chen CH, William I, Sooreshjani M, Bowie M, Hartley G, Dussold C  et al.  STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma.  J Clin Invest  2024 Jun 17;134(12). pii:e175033
  15. Arrieta VA, Gould A, Kim KS, Habashy KJ, Dmello C, Vázquez-Cervantes GI, Palacín-Aliana I, McManus G, Amidei C, Gomez C  et al.  Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas.  Nat Commun  2024 Jun 06;15(1):4698. pii:4698
  16. Habashy KJ, Dmello C, Chen L, Arrieta VA, Kim KS, Gould A, Youngblood MW, Bouchoux G, Burdett KB, Zhang H  et al.  Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma.  Clin Cancer Res  2024 Apr 15;30(8):1619-1629. doi:10.1158/1078-0432.CCR-23-2367
  17. Onkar A, Khan F, Goenka A, Rajendran RL, Dmello C, Hong CM, Mubin N, Gangadaran P, Ahn BC  Smart Nanoscale Extracellular Vesicles in the Brain: Unveiling their Biology, Diagnostic Potential, and Therapeutic Applications.  ACS Appl Mater Interfaces  2024 Feb 14;16(6):6709-6742. doi:10.1021/acsami.3c16839
  18. Moscona-Nissan A, Habashy KJ, Arrieta VA, Sonabend AM, Dmello C  Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.  Oncotarget  2024 Feb 08;15:117-122. doi:10.18632/oncotarget.28549
  19. Arrieta VA, Duerinck J, Burdett KB, Habashy KJ, Geens W, Gould A, Schwarze JK, Dmello C, Kim KS, Saganty R  et al.  ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.  Clin Cancer Res  2024 Jan 17;30(2):379-388. doi:10.1158/1078-0432.CCR-23-1889
  20. Rashidi A, Billingham LK, Zolp A, Chia TY, Silvers C, Katz JL, Park CH, Delay S, Boland L, Geng Y  et al.  Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth.  Cell Metab  2024 Jan 02;36(1):62-77.e8. doi:10.1016/j.cmet.2023.11.013
  21. Fares J, Petrosyan E, Kanojia D, Dmello C, Cordero A, Duffy JT, Yeeravalli R, Sahani MH, Zhang P, Rashidi A  et al.  Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.  J Clin Invest  2023 Dec 15;133(24). pii:e161142
  22. Gould A, Gonzales VAA, Dmello CC, Saganty R, Lukas RV, Zhang DY, Heimberger AB, Canney M, Carpentier A, Desseaux C  et al.  Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas.  Adv Oncol  2023 May;3(1):77-86. doi:10.1016/j.yao.2023.01.017
  23. Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, Gangadaran P, Ahn BC  Tumor microenvironment signaling and therapeutics in cancer progression.  Cancer Commun (Lond)  2023 May;43(5):525-561. doi:10.1002/cac2.12416
  24. Sachdev S, Dmello C, Sonabend AM  Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.  Clin Cancer Res  2023 May 01;29(9):1648-1650. doi:10.1158/1078-0432.CCR-23-0018
  25. Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU  et al.  Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment.  Mol Cancer Res  2023 May 01;21(5):389-396. doi:10.1158/1541-7786.MCR-22-0920
  26. Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, Ellingwood A, Han Y, Lopez-Rosas A, Zannikou M  et al.  STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.  Nat Commun  2023 Mar 23;14(1):1610. pii:1610
  27. Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P  et al.  Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.  Nat Commun  2023 Mar 22;14(1):1566. pii:1566
  28. Becatti M, Dmello C, Kumar B  Editorial: Exploring circular RNAs and their applications within health and disease.  Front Mol Biosci  2023;10:1145738. pii:1145738
  29. Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM  Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.  J Clin Invest  2023 Jan 17;133(2). pii:e163447
  30. Hou D, Castro B, Dapash M, Zolp A, Katz J, Arrieta V, Biermann J, Melms J, Kueckelhaus J, Benotmane J  et al.  B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression.  Res Sq  2023 Jan 09;. pii:rs.3.rs-2399170
  31. Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC  CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.  Front Immunol  2022;13:925985. pii:925985
  32. Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J  et al.  Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.  Clin Cancer Res  2022 Jul 15;28(14):3156-3169. doi:10.1158/1078-0432.CCR-21-2563
  33. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2022 Mar;3(3):373. doi:10.1038/s43018-022-00343-8
  34. Patel D, Dabhi AM, Dmello C, Seervi M, Sneha KM, Agrawal P, Sahani MH, Kanojia D  FKBP1A upregulation correlates with poor prognosis and increased metastatic potential of HNSCC.  Cell Biol Int  2022 Mar;46(3):443-453. doi:10.1002/cbin.11741
  35. Vaidya M, Dmello C, Mogre S  Utility of Keratins as Biomarkers for Human Oral Precancer and Cancer.  Life (Basel)  2022 Feb 25;12(3). pii:343
  36. Mogre S, Makani V, Pradhan S, Devre P, More S, Vaidya M, Dmello C  Biomarker Potential of Vimentin in Oral Cancers.  Life (Basel)  2022 Jan 20;12(2). pii:150
  37. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2021 Dec;2(12):1372-1386. doi:10.1038/s43018-021-00260-2
  38. Zhang DY, Gould A, Happ HC, Youngblood MW, Dmello C, Kang SJ, Canney M, Stupp R, Carvill GL, Sonabend AM  Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner.  Neurooncol Adv  2021;3(1):vdab165. pii:vdab165